Oxford, UK, 19 July 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that the following options over new ordinary shares of 1 penny nominal value (‘Ordinary Shares’) were granted on 18 July 2017 to Directors, PDMRs and employees in line with the Company’s Long Term Incentive Plan. The Company has also made a grant of restricted stock units (‘RSUs’) to to the Non-Executive Directors under the Company’s 2017 Remuneration Policy. Details of both grants are summarised below.
